

13th Annual Global Healthcare Executive Summit

Agenda

Check In

10:00 AM – 11:00 AM **Arrival & Light Breakfast Bites**
Ballroom/Lounge

Speakers & Panelists

11:00 AM – 11:25 AM **Welcome & Introduction: State of Our Global Platform**
Banks Bourne (Bourne Partners)

11:30 AM – 12:10 AM **Partnering with Private Equity as a Catalyst for Transformation**
Jenn Adams (August Bioservices), Tim Dietlin (ELIQUENT Life Sciences), Brandon Ingersoll (MedEquity Capital), Mike Mortimer (GHO Capital Partners) | **Moderator:** Xan Smith

12:15 PM – 12:40 PM **Policy**
John M. O'Brien, PharmD, MPH (National Pharmaceutical Council)

12:40 PM – 1:55 PM **Networking Lunch**

1:55 PM – 2:20 PM **Capital Markets Update**
Jeremy Johnson (Bourne Partners)

2:25 PM – 3:00 PM **Scaling with Purpose: Balancing Growth While Preserving Culture**
Pubali Chakravorty (Promises Behavioral Health), John Chiminski (Former Catalent CEO and Bourne Partners Advisor), Mark Clein (Precision Medicine Group) | **Moderator:** Jake Curtis

3:05 PM – 3:30 PM **What CEOs Need to Know about Generative AI**
Matt Groh, Ph.D. (Northwestern University)

3:35 PM – 4:20 PM **Networking Break**

4:20 PM – 4:50 PM **Fireside Chat**
David Meek (bluebird bio) and Jeremy Johnson (Bourne Partners)

4:55 PM – 5:25 PM **Fireside Chat**
Jimmie Johnson (NASCAR Hall of Fame Driver) and Banks Bourne (Bourne Partners)

Reception

5:30 PM – 6:30 PM **Networking Cocktail Reception**
Pavilion Terrace

13th Annual

Global Healthcare Executive Summit

Speaker Biographies



Banks Bourne

Chief Executive Officer & Founder, Bourne Partners

As Founder and CEO, Banks oversees all business operations and direct investment opportunities at Bourne Partners and Bourne Partners Strategic Capital. Under Banks' leadership, the firm has been party to more than \$10 billion of transactions in the Pharma, Pharma Services and Consumer Healthcare sectors having represented hundreds of closely held / entrepreneur led companies as well as those owned by many of the elite healthcare private equity funds.

Banks is the founder of Tanner Pharma Group, a pharma services company dedicated to providing managed access, commercialization and clinical trials services to patients and partners in more than 100 countries.

Currently, Banks is heavily involved in the firms' investments in PAI Pharma, CadenceRx, Carlin Consumer Health, Eximia Research, MedPharm, and American Injectables. He received a B.A. degree in Business Management from North Carolina State University and an M.B.A. from Wake Forest University. He is a member of Young Presidents Organization (YPO – Gold).

While Banks has derived great satisfaction by offering focused advisory services to, and investing in Pharma, Healthcare, and consumer-oriented companies that need strategic and operational insights; he is even more gratified by knowing that his work has helped companies to improve the health and well-being of patients across the world. He is passionate about providing healthcare and specifically pharmaceuticals to less fortunate patients, as demonstrated by supporting The Bourne Foundation, The Max Foundation and other non-profit organizations. In addition to his passion for a sub-80 round of golf and fresh ski powder, Banks enjoys traveling to new and interesting destinations and spending time with his wife (Molly) and children (Fairbanks and Mary Pope).



Minor Hinson

Head of Private Equity, Senior MD/CIO, Bourne Partners Strategic Capital

Since starting at Bourne Partners in 2011, Minor has been responsible for direct private equity and fund investment activities, has been very involved in both the Phoenix Therapeutics, Inc. joint venture with The Carlyle Group, as well as with the creation, management, and asset disposition of Covis Pharma S.à.r.l ("Covis"). Minor also served on the U.S. Board of Covis from inception to exit and executed investments in AMRI (now Curia), WellDyne, Novitium, iNova, Millicent Pharma, Cadence RX, American Injectables as well as various fund investments.

Minor serves on the Boards and leads the transaction teams on BPSC's investments in Pharmaceutical Associates Inc., Carlin Consumer Health and Medpharm. He additionally serves as Board Observer of Eximia Research. Over the course of his career,

Minor has been involved in over \$10 billion of financial transactions spanning the range of venture investing, private equity, mezzanine and senior debt, project finance debt and equity, cross boarder preferred stock issuances, sell-side, and buy-side M&A transactions (both large cap and middle market), and other corporate finance advisory assignments.

Minor began his business career in 1984 in Corporate Banking at NationsBank/Bank of America and became a Senior Relationship Manager in the Baltimore/Washington loan production office before deciding to attend business school in 1990. After an M.B.A. internship in corporate finance at The Coca Cola Company in Atlanta, Minor accepted a position as an Associate at Bowles Hollowell Conner & Company in Charlotte. Minor returned to Bank of America in 2002 to join the Strategic Investment Group, a group he eventually managed. He was then recruited to manage Corporate Development for the bank's Global Treasury Services (\$4 billion in profit). In 2007, Minor accepted a position to join Christofferson Robb & Company to raise capital and work on the initial London project team of the firm's 300 MW offshore wind farm (Thanet Offshore Wind Limited) which, when opened, was the world's largest offshore wind project.

Minor received a B.A. in Economics from Davidson College in 1984, as well as an M.B.A. (honor society) in 1992 from The Kenan-Flagler Business School at UNC Chapel Hill. Most importantly, Minor has been married to his wife, Tiffany, for over 26 years and is the father of two Children – Minor (college) and Sara Frances (high school).



Jake Curtis

Vice President, Bourne Partners

Jake joined Bourne Partners in 2022. He provides transaction execution support on a variety of M&A transactions across the Pharma Services sector.

Before joining the team, Jake was a Senior Analyst at Crosstree Capital Partners, working in the Pharma Services group. Jake began his career with Bourne Partners when he joined the firm as an intern in 2019. He graduated from the University of North Carolina at Charlotte with a B.S. in Finance.



Jeremy Johnson

Senior Managing Director & Head of Investment Banking, Bourne Partners

Jeremy has 25 years of healthcare-focused M&A and private equity experience. He has been with Bourne Partners since 2006 and is part of the core leadership team at the firm. Jeremy currently serves as a Senior Managing Director, overseeing the broker dealer and all Investment Banking activities. Today Jeremy is focused on proactively growing the investment bank, including expanding its coverage and service offering more broadly across the healthcare and life sciences market.

Prior to Bourne Partners, Jeremy was a founding member and Managing Director at Madison Keats, a life sciences strategy and consulting firm. Jeremy began his career at VentureWorx, an Internet incubator. He is a graduate of Georgetown University

where he earned a Bachelor of Arts in Economics.

Outside of work, Jeremy is active in the community. He is a member of Leadership Charlotte and an avid supporter of a few personally important charitable foundations. In addition, he remains highly active with Georgetown University. Jeremy is a native of North Carolina and currently lives in the same neighborhood in south Charlotte where he grew up. He is married to his wife,

Jessica, and they have three young children who attend the same schools Jeremy attended when he was their age. When he's not chasing down a deal, Jeremy enjoys spending most of his free time with his wife and kids.



Matthew Bullard

Strategic Advisor, Bourne Partners

Matthew Bullard is an accomplished healthcare-focused investment professional with over 20 years of life sciences experience and a track record of over \$5 billion of specialized financings.

Matt is a former Managing Director at HealthCare Royalty Partners where he was responsible for identifying, structuring, and negotiating investments across royalty monetization, revenue interest financing, and debt strategies. Previously, Matt was a Partner at leading life sciences and healthcare investor NovaQuest Capital Management where he focused on product-based investments in late-stage clinical and commercial biopharma programs.

As a Strategic Advisor at Bourne Partners, Matt supports royalty monetization activities in Bourne Partners' investment banking advisory team, through deal origination structuring, and execution.



Oliver White

Associate, Bourne Partners

Oliver White joined Bourne Partners in 2023 and is a key member of its royalty monetization and non-dilutive financing coverage team. Prior to joining Bourne Partners, Oliver spent five years with Tanner Pharma Group (a Bourne Partners portfolio company) where he supported a range of US and European biopharma companies in facilitating access to innovative rare disease and oncology drugs for patients in countries where they are not yet commercially available.

Oliver holds an M.S. in Chemistry from the University of Durham, England. During his studies, Oliver gained industry R&D experience with Vertex Pharmaceuticals and completed his Master's research placement at Université Grenoble-Alpes, France.



Jimmie Johnson

Seven-time NASCAR Cup Series Champion

Jimmie Johnson is not only one of the greatest racecar drivers of the modern era - but he is also one of the most accomplished professional athletes in sports. A seven-time NASCAR Cup Series champion, Johnson remains the only racecar driver in history to be named The Associated Press Male Athlete of the Year (2009). He continually defies critics, while chasing his aspirations and dreams with grace, humility, and class. Throughout Johnson's storied career, he and the No. 48 team of Hendrick Motorsports recorded 83 wins in 686 starts, tying him with his childhood hero, Cale Yarborough for sixth on the all-time wins list. He shares the record of seven championship titles with NASCAR Hall of Fame legends Richard Petty and Dale Earnhardt, Sr.

Johnson was the "MVP" in one of the greatest championship runs ever seen in sports as the No. 48 team won five titles in a row, recording 35 wins from 2006 to 2010. He also won the 2013 NASCAR Cup Series championship and his seventh - and final - historic championship came at the conclusion of the 2016 season. His legacy in NASCAR will transcend generations.

At the conclusion of the 2022 season Johnson returned ‘home’ to NASCAR with race team Petty GMS, announcing Johnson entered into an ownership agreement with entrepreneur Maurice “Maury” Gallagher and the original founder of the team, Richard Petty “The King”. In January 2023, the team was renamed to LEGACY MOTOR CLUB. The CLUB competes with the Nos. 42 and 43 Toyota entries and a part-time schedule for Johnson in the No. 84.

In 2024, Johnson was inducted into the NASCAR Hall of Fame, the International Motorsports Hall of Fame and the West Coast Stock Car Hall of Fame for his record-breaking accomplishments on the track throughout his illustrious career.

Johnson and wife Chandra are co-founders of the Jimmie Johnson Foundation (JJF), which focuses on K-12 public education. The JJF has contributed more than \$13 million to organizations and schools in need across the U.S., since its inception in 2006. Johnson has published two books throughout his career; *On the Road* and *One More Lap: Jimmie Johnson and the No. 48*. Johnson is a podcast host, (*Never Settle with Jimmie Johnson and Marty Smith*), co-owner of Happenstance Media Co.; investor in various businesses; and enjoys fitness, skiing and art. The Johnsons reside in Charlotte, N.C., with daughters Genevieve and Lydia.



John Chiminski

Chairman, Catalent

John Chiminski was named Chief Executive Officer of Catalent, Inc. in March 2009 and appointed Chair of the Catalent Board in October 2016. He then served as Catalent’s Executive Chair from June 2022 to June 2023, as part of a planned succession of a new CEO and transition to an independent Chair of the Catalent BoD.

Mr. Chiminski partnered with the PE firm Blackstone to complete a carve-out of the Catalent business from Cardinal Health and transform it to its current position as a market leader in biopharma services. Included in that transformation was a

fully independent public company in October 2016. Under a decade of his leadership, Catalent’s revenue grew 8% CAGR at constant currency and its enterprise value more than quintupled to \$18.5 billion.

Mr. Chiminski has a diversified medical diagnostics and pharmaceutical background that includes operations leadership, product development and services, with a track record of growing global businesses.

He joined Catalent after more than 20 years at GE Healthcare. From 2007 until 2009, Mr. Chiminski served as President and CEO of GE Medical Diagnostics, a global business with sales of \$1.9 billion. From 2005 to 2007, he served as Vice President and General Manager of GE Healthcare’s global magnetic resonance business, and, from 2001 to 2005, Mr. Chiminski served as Vice President and General Manager of Global Healthcare Services. Earlier in his career, Mr. Chiminski held a series of cross-functional leadership positions in both operations and engineering, including GE Medical Systems assignments in France.

Mr. Chiminski holds a bachelor’s degree from Michigan State University and a master’s degree from Purdue University, both in electrical engineering, as well as a master’s degree in management from the Kellogg School of Management at Northwestern University. In 2012, he received a Distinguished Engineering Alumni award from Purdue for his record of accomplishments. In 2019, Mr. Chiminski was the first recipient of the CPHI Lifetime Achievement Award for a distinguished career in the biotech or pharmaceutical arena. He is a Senior Advisor at Abingworth, a bioscience investment firm, and previously served as a director of PhenomeX, DJO Global as well as Graham Packaging. Married with three children, Mr. Chiminski lives in Southeastern Florida.



Jenn Adams

Chief Executive Officer, August Bioservices

Jenn Adams is an executive with over 30 years of experience providing strategic and operational leadership for both large public corporations and private growth-stage companies. She has deep domain expertise in sterile injectable pharmaceutical development, manufacturing, and commercialization.

Jenn currently serves as Chief Executive Officer at August Bioservices, a Nashville-based CDMO focused on providing sterile injectable development and manufacturing services to the biopharmaceutical and biotechnology space, a position she has held since founding the company in 2020.

Prior to this role, she held the position of SVP & President of AmerisourceBergen's Clinical Product Solutions Business Unit. Ms. Adams spent her early career at Baxter Healthcare, serving in leadership roles in the Medication Delivery and Fenwal businesses. Jenn also serves as Senior Advisor to Oak HC/FT, a venture growth-equity fund investing in healthcare information and services.

Ms. Adams serves as Board Chair, and a member of the Executive Committee, for Life Science Tennessee, and also serves as a Director on the Board of Eton Pharmaceuticals, a publicly traded pharmaceutical company. Jenn holds an MBA from Northwestern University's J.L. Kellogg Graduate School of Management.